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A B S T R A C T
Background
Abnormal delayed relaxation of skeletal muscles, known as myotonia, can cause disability in myotonic disorders. Sodium channel
blockers, tricyclic antidepressive drugs, benzodiazepines, calcium-antagonists, taurine and prednisone may be of use in reducing
myotonia.
Objectives
To consider the evidence from randomised controlled trials on the efficacy and tolerability of drug treatment in myotonia .
Search methods
In July 2009 we updated the searches of the Cochrane Neuromuscular Disease Group Trials Specialized Register , The Cochrane Central
Register of Controlled Trials (The Cochrane Library Issue 3, 2009), MEDLINE (from January 1966) and EMBASE (from January
1980). We hand searched the grey literature and contacted disease experts and anti-myotonic drug manufacturers.
Selection criteria
We considered all (including quasi) randomised trials of participants with myotonia treated with any drug treatment versus no therapy,
placebo or any other active drug treatment.
Primary outcome: reduction of clinical myotonia.
Secondary outcomes:
(1) clinical relaxation time; (2) electromyographic relaxation time; (3) stair test; (4) presence of percussion myotonia; and (5) adverse
events.
Data collection and analysis
Two review authors extracted the data independently onto standardised extraction forms. Meta-analysis was not possible.
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Main results
No new trials were found for this update.Ten double-blind or single-blind crossover studies involved a total of 143 participants of
whom 113 had myotonic dystrophy type 1 and 30 had myotonia congenita. The studies were of poor quality and did not provide
adequate data.Two small crossover studies without a washout period demonstrated a significant effect of imipramine and taurine in
myotonic dystrophy. One small crossover study with a washout period demonstrated a significant effect of clomipramine in myotonic
dystrophy. Meta-analysis was not possible.
Authors’ conclusions
Due to insufficient good quality data and lack of randomised studies, it is impossible to determine whether drug treatment is safe
and effective in the treatment of myotonia. Larger, well-designed randomised controlled trials are needed to assess the efficacy and
tolerability of drug treatment for myotonia.
P L A I N L A N G U A G E S U M M A R Y
Drug treatment for myotonia (delayed muscle relaxation after contraction) in muscle diseases such as myotonic dystrophy and
myotonia congenita
Myotonia is an abnormal delay in the relaxation of muscles after contraction. It is a key symptom in a number of muscle diseases called
myotonic disorders. It can be mild or severe, interfering with daily activities such as walking, climbing stairs or opening and closing
the eyelids. It can be worse after periods of rest or triggered by cold or fatigue. People with mild myotonia can manage their disease
without medication but in severe cases treatment is usually necessary. Drugs that have been used to treat myotonia include sodium
channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine,
benzodiazepines, calcium antagonists, taurine and prednisone. This review describes ten randomised controlled trials which tested the
effectiveness of twelve different drug treatments. The review was updated in July 2009 and no new trials were found. The ten trials
included a total of 143 participants of which 113 had myotonic dystrophy and 30 had myotonia congenita. The trials were generally
small and of poor quality. Meta-analysis was not possible due to a lack of appropriate trials and data. Two small studies suggested
that clomipramine and imipramine might have a short-term beneficial effect on the myotonia in myotonic dystrophy and one small
study suggested that taurine might have a long-term beneficial effect in myotonic dystrophy. Minor side effects such as dry mouth
and dizziness were reported with clomipramine and imipramine, but not with taurine. It was not possible to determine whether drug
treatment is safe and effective for myotonia in people with a myotonic disorder based on the evidence from the ten trials included in
this review. Larger, well-designed randomised controlled trials are needed.
B A C K G R O U N D
Myotonia is a clinical phenomenon, which refers to a delayed
muscle relaxation after voluntary or evoked muscle contraction
(Logigian 2005). It is a cardinal feature of myotonic disorders in-
cluding myotonic dystrophy and the non-dystrophic myotonias.
Myotonia may be present in every skeletal muscle. Clinical ex-
amination reveals action myotonia and percussion myotonia, or
both. Action myotonia and percussion myotonia are best tested in
the hand muscles: following a forceful grip, the ability to relax the
grip is delayed (action myotonia or grip myotonia); or mechanical
stimulation, for example a blow with the percussion hammer on
the thenar muscles will also contract the muscle for a few seconds
(percussion myotonia). Furthermore, an acute muscle contraction
may give a transient decline in muscle force (transient paresis)
(Drost 2001; Ricker 1978). Repeated contraction and relaxation
may improve myotonia as well as muscle force, which is called
the ’warming-up’ phenomenon. However, in a condition called
paramyotonia, the myotonia worsens after repetitive contractions
(paradoxical myotonia).
A number of conditions are associated with delayed relaxation of
muscles in a way that resembles myotonia but they do not have the
characteristic electrophysiological features of truemyotonia (pseu-
domyotonia) (Harper 2001). Because such pseudomyotonia may
have a different physiological basis from true myotonia, we ex-
cluded these conditions fromour review. These conditions include
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McArdle’s disease (glycogenosis type V), Hoffman’s disease (my-
otonia in hypothyroidism), Brody’s disease (sarcoplasmic reticu-
lum-Ca2+ATPase deficiency), neuromyotonia, neuroleptic malig-
nant syndromes and tetanus. Schwartz-Jampel syndrome (chon-
drodystrophia myotonia) was also excluded because myotonic ac-
tivity in this disease persists during general anaesthesia, which does
not happen in true myotonia (Fowler 1974). True myotonia syn-
dromes included in this review are discussed below.
Myotonic dystrophy
Myotonic dystrophy type 1 is an autosomal-dominant disorder
in which myotonia is accompanied by a characteristic pattern
of muscle weakness and by the involvement of several organs
(Cürschmann 1912;Harper 2004; Steinert 1910). This condition
is caused by an expanded CTG (cytosine-thymine-guanine) trin-
ucleotide repeat in the DMPK-gene on chromosome 19q (Brook
1992; Harley 1992). The inheritance is characterised by anticipa-
tion, that is the earlier and more severe onset of the disease in suc-
cessive generations (Howeler 1989). The prevalence of myotonic
dystrophy type 1 varies from 2 to 12 per 100,000 (Emery 1991).
Myotonia is clinically detectable in almost every symptomatic pa-
tient. Recently, myotonic dystrophy type 2 was described, which
differs from type 1 in its predominant proximal muscle weakness.
It was, therefore, originally named proximal myotonic myopathy
(PROMM) (Moxley 1996; Ricker 1999). Myotonic dystrophy
type 2 is caused by an increased CCTG repeat in the ZNF9 gene
on chromosome 3. We have included people with clinical myoto-
nia due to both types of myotonic dystrophy.
Non-dystrophic myotonias
Clinically non-dystrophic myotonias havemyotonia with or with-
out periodic paralysis (Rüdel 1999). Recently the molecular basis
of these disorders has been discovered, but it is difficult to make
a diagnosis on the basis of the clinical picture because no obvi-
ous genotype-phenotype correlation exists (Koty 1996; Papponen
1999; Plassart -Schiess 1998).Over the past decade, a combination
of electrophysiologic andmolecular biological studies have led to a
reclassification of this group of diseases (Drost 2001; Ptácek 1998;
Rüdel 1997; Rüdel 1999). They are now classified as chloride or
sodium channel diseases.
Chloride channel disorders
There are two forms of chloride channel disorders: autosomal-
recessive myotonia congenita (Becker’s disease) (Becker 1970;
Becker 1977) and autosomal-dominant myotonia congenita
(Thomsen’s disease) (Thomsen 1876). Both diseases are charac-
terised by clinical myotonia. Autosomal-recessive myotonia con-
genita also shows transient paresis (Drost 2001; Ricker 1978). The
disorders are caused by a mutation in the skeletal muscle chlo-
ride channel gene (CLCN1) on chromosome 7q (Fontaine 1997;
George 1993; Koch 1992). The prevalence of chloride channel
diseases varies in different studies between 2 to 7.3 per 100,000
(Baumann 1998; Becker 1977; Rüdel 1994). We included all pa-
tients with dominant and recessive myotonia congenita in our re-
view.
Sodium channel disorders
Sodium channel disorders are all autosomal-dominantly inherited
or sporadic and are divided into paramyotonia congenita, potas-
sium-aggravated myotonia (myotonia fluctuans, myotonia perma-
nens and acetazolamide responsive myotonia congenita) and hy-
perkalaemic periodic paralysis (hyper PP) (Lehmann-Horn 1994;
Lennox 1992; Lerche 1993; Ricker 1990; Ricker 1994). The
sodium channelopathies are caused by a mutation in the muscle
sodium channel gene (SCN4A) on chromosome 17q encoding for
SkM1, the alpha-subunit of the sodium channel (Fontaine 1990;
Fontaine 1997). The exact prevalence of sodium channel diseases
is not known although the prevalence of paramyotonia congenita
has been estimated at 1 per 356,000 (Becker 1970). Hyper PP
can occur with myotonia or paramyotonia and sometimes with-
out either. We excluded Hyper PP without (para)myotonia and
included all other sodium channel disorders in our review.
The pathophysiological mechanisms in the several myotonic dis-
orders are different. Recent publications suggest that the expanded
CTG-repeat in myotonic dystrophy triggers aberrant splicing of
chloride channel mRNA (Charlet-B 2002; Mankodi 2002) but it
is also possible that the myocytes in myotonic dystrophy display
an abnormal Na+ channel activity (Bernareggi 2005). Thus, the
exact pathophysiological mechanism leading to myotonia in my-
otonic dystrophy is unknown. It could be assumed that there is an
overlap with the non-dystrophic channelopathies.
The chloride channel myotonias are caused by a permanent re-
duction of the resting chloride conductance of the muscle fiber
membranes (Franke 1991; Lipicky 1979). Normal chloride con-
ductance is necessary for a fast repolarisation of the muscle fiber
membranes, otherwise these tend to stay depolarised causing my-
otonia (Jurkat-Rott 2001) or become hyperdepolarised causing a
loss of excitability of the muscle fiber membrane and thereby a
transient paresis.
Sodium channel myotonias are caused by a long-lasting depolari-
sation of the muscle fiber membrane due to an inactivation defect
of the sodium channels (Lehmann-Horn 1987a; Lehmann-Horn
1987b). These can initiate successive action potentials, which is
the basis for myotonia (Jurkat-Rott 2001).
Many people with mild myotonia can manage their disease with-
out medication. Severe myotonia can interfere with daily activities
and in these individuals treatment is often necessary. No treatment
for the cause of myotonia is available so treatment is merely symp-
tomatic. In general drugs that block the sodium channels, inde-
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pendent of the disease process involved, can diminish myotonia.
These agents reduce the excitability of the cell membrane of the
skeletal muscle and include local anaesthetics,cardiac agents, such
as anti-arrhythmic drugs, and anti-epileptics.
The first treatment for myotonia was published by Wolf in 1936
who treated four people with myotonia congenita with quinine,
an anti-arrhythmic drug (Wolf 1936). The literature also suggests
that procainamide, tocainide and phenytoin have favourable ef-
fects (Dengler 1979; Kwiecinski 1992; Leyburn 1960; Munsat
1967; Rüdel 1980; Streib 1986). However, procainamide and to-
cainide could have serious long-term side effects. Expert opinion
suggests that mexiletine is the agent of first choice (Rüdel 1994).
However the published evidence basis for this opinion is unclear.
There are some case reports (Ceccarelli 1992; Leheup1986; Pouget
1983), one study with a heterogeneous population (Kwiecinski
1992) and an electrophysiological evaluation (Rossi 1985) on the
use of mexiletine in people with myotonia in the literature. Aceta-
zolamide is a carbonic anhydrase inhibitor traditionally thought
of as a diuretic, but it has been described as useful for myotonia
in some sodium channelopathies (Griggs 1978; Ptácek 1994).
A crucial aspect to this review is how to quantify myotonia because
it can be difficult to standardize this as highlighted by a report
of an experimental protocol to quantify myotonia using quanti-
tative muscle assessment (Sansone 2000). The problems include
the variability of the myotonia between people and within a given
patient at different times of the day, and how to take account of
the warm up phenomenon all of which exacerbate the usual prob-
lem of inter rater variability. Possible solutions might be the use
of specific devices with a computerized protocol (Logigian 2004;
Logigian 2005). One of the most used parameters of myotonia is
the relaxation time after maximum voluntary contraction (MVC)
as measured by stopwatch, special technical equipment or com-
puterized protocols. A related measure is the electromyographic
variant, the electromyographic (EMG) relaxation time afterMVC.
Another used parameter is to record the presence or absence of
percussion myotonia. These parameters measure the impairment,
but not the functional effect of myotonia. The stair test (time
needed to climb ten stairs) is possibly the best available method
for measuring approximate functional benefit.
No systematic reviews of drug treatment for myotonia are known.
Two non-systematic reviews of therapy for the myotonic disorders
have been published (Meola 2000; Meola 2004). This systematic
review aims to provide the evidence on which to base treatment.
O B J E C T I V E S
To consider the evidence from randomised controlled trials on the
efficacy and tolerability of drug treatment in people with clinical
myotonia due to a myotonic disorder.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised and quasi-randomised (alternate or
other systematic treatment allocation) trials of any drug treatment
in people with clinical myotonia due to one of the myotonic dis-
orders described below.
Types of participants
Participants of all ages with clinical myotonia caused by myotonic
disorders such as myotonic dystrophy and the non-dystrophic my-
otonias were included. It is now possible to diagnose the myotonic
disorders byDNA-analysis. This was not possible at the time when
the included studies were performed so DNA-analysis was not an
inclusion criterion in our review.
We excluded people with McArdle’s disease (glycogenosis type V),
Hoffman’s disease (myotonia in hypothyroidism), Brody’s disease
(sarcoplasmic reticulum-Ca2+ATPase deficiency), neuromyotonic
diseases, neuroleptic malignant syndromes, tetanus and Schwartz-
Jampel syndrome. For trials or treatment groups including peo-
ple with myotonic dystrophy and non-dystrophic myotonias we
described the different diseases and the degree of myotonia sepa-
rately, if this was possible.
Types of interventions
We included any drug treatment (given either singly or in com-
bination) versus no therapy, placebo or another active drug treat-
ment. The list of potential drugs included quinine, procainamide,
tocainide, phenytoin, mexiletine and acetazolamide but this list
was not exclusive.
Types of outcome measures
Primary outcomes
As there is no consensus regarding the best measure of myotonia
leading to disparate outcome measures in each of the randomised
trials, we devised a measure using a categorisation of the changes
in clinical myotonia after drug treatment for each trial based on
the conclusion of the original authors as follows:
1. improvement of myotonia with no residual clinical
myotonia;
2. improvement of myotonia but still clinically detectable;
3. no change of myotonia;
4. worsening of myotonia.
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Secondary outcomes
1. Relaxation time: the time taken to fully open the hand after
a maximum voluntary contraction (MVC) (hand-grip
myotonia). This might be determined manually by stopwatch or
by computerized protocols. When using a computerized hand-
grip myometer the decline in maximum voluntary contraction
from 90 to 5%, during relaxation is frequently used to measure
the relaxation time. However some researchers have used 50%,
75% or 100% decline from peak MVC as the relaxation time.
We included all such protocols.
2. Electromyographic (EMG) relaxation time: the
phenomenon of myotonia can be recorded with an
electromyographic needle electrode and are seen as positive
waves, so called myotonic discharges or after-discharges. After
MVC these myotonic or afterdischarges wax and wane and
finally stop. The duration of these after-discharges is also called
EMG relaxation time. For example after-discharges can be
recorded from the opponens pollicis muscle.
3. Stair test: time needed to climb ten stairs
4. Presence of percussion myotonia: percussion myotonia is
myotonia occurring after a mechanical stimulus; for example
tested using percussion of the thenar muscles of the hand with a
reflex hammer.
5. The occurrence of one or more adverse events during
treatment with the different agents. We specified the adverse
events.
For all outcome measures we used a minimum treatment duration
of oneweek andmaximum treatment duration of twelveweeks and
where necessary planned to adjust for different follow-up periods.
Search methods for identification of studies
See: Cochrane Neuromuscular Disease Group search strategy.
Electronic searches
The Cochrane Neuromuscular Disease Group Trials Special-
ized Register was searched using: ’myotonia’, ’myotonic dystro-
phy’, ’non-dystrophic myotonias’, ’myotonia congenita’, ’Mor-
bus Thomsen’, ’Morbus Becker’, ’potassium-aggravated myoto-
nia’, ’myotonia fluctuans’, ’myotonia permanens’, ’paramyotonia
congenita’, ’hyperkalaemic periodic paralyses’, ’relaxation’ AND
’muscle’ and ’treatment’ OR ’therapy’ as the primary search items
(July 2009). We adapted this strategy to search The Cochrane
Central Register ofControlledTrials (CENTRAL) (TheCochrane
Library Issue 3, 2009), MEDLINE (January 1966 to July 2009)
and EMBASE (January 1980 to July 2009). See Appendix 1, Ap-
pendix 2 and Appendix 3 for MEDLINE, EMBASE and CEN-
TRAL strategies. Following the initial publication of this review
in January 2006, searches were updated in December 2007 and
again in July 2009.
Searching other resources
Grey literature such as neuromuscular text books (Myology) and
abstracts from international neuromuscular congresses (WMS/
AAN) were handsearched and we checked the reference lists of
the identified literature and reviews concerning myotonia.We also
contacted authors, disease experts and manufacturers of anti-my-
otonic drugs.
Data collection and analysis
Selecting trials for inclusion
Two review authors (JT and CGF) independently reviewed the
titles and abstracts from the electronic search to identify relevant
trials for full review. The full text of all potentially relevant studies
was obtained for assessment. The review authors decided which
trials fitted the inclusion criteria and graded their methodological
quality. Disagreement was resolved by discussion. Review authors
were not blinded to trial authors’ names, institutions and the jour-
nals of publication.
Assessment of methodological quality
Two review authors (JT and CGF) independently assessed ran-
domised trials for methodological quality with respect to the fol-
lowing items: allocation concealment, patient blinding, observer
blinding, explicit diagnostic inclusion and exclusion criteria and
explicit outcomemeasures. These items were assessed according to
the Cochrane approach: A - adequate, B - unclear, C - inadequate,
D - not done. Disagreement was resolved by discussion.
Data extraction
Data extraction on participants, methods, intervention, outcomes
and adverse events was performed independently by two review
authors (JT and CGF) using a data extraction form.We attempted
to obtain missing data from the trial authors if this was necessary.
For the primary outcome we had created a special scoring system:
(1) no residual clinical myotonia; (2) improvement of myotonia
but still clinically detectable; (3) no change; (4) worsening of my-
otonia; and data were transformed from the original studies by
two review authors (JT and CGF) with any disagreement being
resolved by discussion.
Analysis
For statistical analysis of the primary outcome we dichotomised
the variable scoring systems to define two groups:
(1) no residual myotonia or an improvement
(2) no change or worsened.
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Risk ratios (RRs) with 95% confidence intervals (CI) were to be
calculated from the dichotomised data for each study if this was
possible. Where possible the numbers needed to treat (NNT) and
the numbers needed to harm (NNH) would also have been calcu-
lated. If all necessary data could be deduced from the published
results, the primary outcome for crossover studies were analysed
using the McNemar’s test (Armitage 1987; Breslow 1980), calcu-
lating the odds ratios. If there had been continuous data in the
secondary outcomeswewould have calculated themean difference
(MD) with 95% CI or presented the original statistical analysis of
the study. If there had beenmore than one trial with the same agent
in the same disease group we would have calculated a weighted
treatment effect across those trials using a fixed-effect model with
the Cochrane statistical package, Review Manager (RevMan). We
interpreted a P value less than or equal to 0.05 as statistically sig-
nificant. If chi-squared analysis showed heterogeneity of the study
results (P < 0.1), sensitivity analyses would have been carried out
to explore plausible causes. If heterogeneity could still not be ex-
plained, we would have reported the results using a random-ef-
fects model. We would have analysed myotonic dystrophy and
the non-dystrophic myotonias as subgroups if possible, however,
we did not analyse them as a total group. We also discussed ad-
verse events and cost benefits drawing upon non-randomised data
(Dukes 2000).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See Tables: Characteristics of included studies and Characteristics
of excluded studies.
The original search revealed nine trials that compared active drug
treatment with placebo for the treatment of myotonia, in a total
of 103 participants with myotonic dystrophy type 1 and 30 par-
ticipants with myotonia congenita (Antonini 1990; Durelli 1983;
Kratz 1986; Gascon 1989; Grant 1987; Kwiecinski 1992; Lewis
1966; Leyburn 1960; Munsat 1967). One trial was found that
compared two different drug treatments for the treatment of my-
otonia, in 10 participants with myotonic dystrophy type 1 (Finlay
1982). On the basis of the title or the abstract a further 34 studies
initially appeared to be eligible. However, by reading the full text
of all potentially relevant studies 17 were non-randomised or un-
controlled studies (Backman 1990; Birnberger 1975; Brumback
1983; Durelli 1982; Griggs 1977; Griggs 1978; Guilleminault
1984; Mielke 1985; Milner-Brown 1990; Müller 1980; Orndahl
1986; Ricker 1980; Rüdel 1980; Samaha 1964; Sechi 1983;
Sugino 1998; Matsumura 2004), ten were case studies (Alfonsi
2007; Benstead 1987; Cook 1984; Garai 1954; Geschwind 1955;
Hughes 1991; Jackson 1994; Karli 1974; Pendefunda 1974; Streib
1987) and a further seven did not have measures of myotonia as
outcomemeasures (Griggs 1989;Orndahl 1994; Pénisson-Besnier
2008; Schneider-Gold 2003; Vlachopapadopoulou 1995; Walter
2002; Tarnopolsky 2004).
Another study (Martens 2005) is awaiting assessment because at
the time of writing this review the trial results were not available in
sufficient detail. We were informed about this study by contacting
one of the disease experts in this field and read the abstract. When
this trial is published in full, it will be included in the next update
to the review.
When we repeated the searches in July 2009, 8 new references
were obtained form the NMDRegister, 28 from CENTRAL, 171
from MEDLINE, and 108 from EMBASE but none were new
RCTs eligible for inclusion.
Trial design
Eight included trials were placebo-controlled, randomised, dou-
ble-blind, crossover studies. The other two were placebo-con-
trolled, randomised, single-blind, crossover studies (Grant 1987;
Kwiecinski 1992). All included trials were performed in a single
centre and a total of 143 participants received treatment (active
drug or placebo) over two weeks to six months. In Antonini 1990
the treatment period was separated by a 30-day period washout
interval. The other nine trials had no washout interval between
the treatment periods.
The trial of Kwiecinski 1992 started as a crossover study. After-
wards randomisation for three different study drugs took place.
Remarkably the sum of the number of participants in the different
treatment groups in the randomised part of the study exceeded
the total number of included participants. An attempt to clarify
this with the author was unsuccessful. We assume the second part
of the study was not randomised until we receive evidence to the
contrary.
Participants
The trials did not provide baseline characteristics of the individual
participants or of the two separated groups. Five trials did not give
the baseline characteristics at all (Durelli 1983; Kratz 1986; Lewis
1966; Leyburn 1960;Munsat 1967), the other trials gave the char-
acteristics of the entire study population. Five trials included peo-
ple withmyotonic dystrophy only and five trials (Kwiecinski 1992;
Kratz 1986; Lewis 1966; Leyburn 1960; Munsat 1967) included
participants with myotonic dystrophy as well as myotonia con-
genita. Five trials did not define explicit inclusion criteria (Finlay
1982; Kratz 1986; Gascon 1989; Lewis 1966; Leyburn 1960).
Only Antonini 1990 defined explicit exclusion criteria. In this trial
cardiac, ophthalmologic or urologic diseases were excluded. Since
cardiac and ophthalmologic symptoms are features of myotonic
dystrophy, this trial probably included a selected group of patients.
6Drug treatment for myotonia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Interventions
The regimens of treatment varied between studies (see
Characteristics of included studies). Most studies used drugs that
block sodium channels (procainamide, disopyramide, phenytoin,
quinine, tocainide and mexiletine) by which myotonia is dimin-
ished by reducing the level of depolarisation. Other drugs used
were clomipramine, imipramine, taurine, nifedipine, diazepam
and prednisone. It is hypothesised that the tricyclics (imipramine
and clomipramine) act on the sympathetic nerve terminals to in-
crease levels of norepinephrine, which exerts an inhibitory influ-
ence on skeletal muscle membranes by ß2-adrenoreceptor stim-
ulation (Bowman 1981; Gascon 1989). Taurine, an amino-acid,
may affect cellular hyperexcitability by increasing membrane con-
ductance of potassium and chloride (Durelli 1982; Durelli 1983).
All these types of drugs seem to act as membrane-stabilisers.
Outcome measures
The outcome measures used differed between trials. The most
frequently used outcome measure was the clinical relaxation time
in seconds. It was measured after three seconds (Antonini 1990),
two to three seconds (Gascon 1989), five seconds (Lewis 1966) and
three minutes (Finlay 1982) of maximum voluntary contraction
(MVC). Others (Grant 1987; Kratz 1986; Kwiecinski 1992) did
not specify the length of maximum voluntary contraction. The
EMG relaxation time (after-discharge) in seconds after MVC was
also used (Durelli 1983; Kratz 1986; Kwiecinski 1992). Additional
ways of measuring relaxation time were used such as the use of
EEG surface electrodes (Lewis 1966) or an ergographic device
(Munsat 1967). Two trials used a mean score of three relaxation
times (Gascon 1989; Lewis 1966) and one used a mean score
of five relaxation times after MVC (Grant 1987). Another trial
used a mean score of six measurements consisting of three clinical
relaxation times and three EMG relaxation times (Leyburn 1960).
Other outcome measurements were occurrence of percussion my-
otonia (Durelli 1983), percussion myotonia in seconds (Gascon
1989), lid myotonia in seconds after firm closure (Kwiecinski
1992), occurrence of myotonic discharge induced by electrical
stimulation of the median nerve (Durelli 1983), potassium chlo-
ride (KCl) loading test in mmol/litre for occurrence of myotonia
(Durelli 1983), time to climb ten stairs (stair test) (Kwiecinski
1992) and subjective responses (Finlay 1982; Kwiecinski 1992).
Analysis
All trials were analysed on a per protocol basis instead of an inten-
tion-to-treat basis (withdrawals were not included in the analysis).
Risk of bias in included studies
See Additional Table 1.
The methodological quality assessment took into account alloca-
tion concealment, patient blinding, observer blinding, explicit in-
clusion and exclusion criteria and explicit outcome measures. We
graded these items as: A: adequate, B: unclear, C: inadequate, D:
not done. If the information was not available the item was graded
as unclear. The scores of each trial are included in Additional Table
1.
In all ten trials participants were randomised for crossover stud-
ies to either active treatment or placebo (or another active drug
treatment). The allocation concealment was considered adequate
in the study Leyburn 1960; a statistician randomised trial partici-
pants. For Lewis 1966 the allocation concealment was inadequate;
the procedure was described as “arbitrary by secretary”. The other
allocation concealments were unclear, because the method of ran-
domisation was not explained.
Patient blinding was intended in at least nine trials. In only
three trials the blinding was considered adequate (Durelli 1983;
Kwiecinski 1992; Munsat 1967). In six trials the blinding was un-
clear because it was not described (Antonini 1990; Gascon 1989;
Grant 1987;Kratz 1986; Lewis 1966; Leyburn 1960) and inFinlay
1982 the patient blinding was inadequate because participants
could recognise the side effects having used the medication pre-
viously in a clinical setting. Observer blinding was also intended
in at least nine trials. Four trials were considered adequate for ob-
server blinding (Durelli 1983; Finlay 1982; Gascon 1989; Lewis
1966). In one trial the observer could recognize the origin of the
medication by the kind of adverse events (Munsat 1967). Another
single trial did not have observer blinding (Kwiecinski 1992) and
the study of Grant 1987 was designed as a randomised single-
blind crossover study but it was unclear if the participants or the
observers were blinded. The other two studies were unclear. None
of the trials recorded effectiveness of blinding.
We also graded the inclusion and exclusion criteria. This item is
discussed under participants in the Description of studies section.
As expected there was no uniform outcome measurement. The
explicit outcome measurements were considered adequate in eight
trials. We considered the outcome measure of Leyburn 1960 as
inadequate only because it was themean value of sixmeasurements
in which three were EMG relaxation times and three were clinical
relaxation times. It is difficult to give an explanationof themeaning
of these values. Moreover, some studies took the mean of three to
five relaxation times. It is likely that these times are shortened by
the warming-up phenomenon.
Effects of interventions
A total of ten single centre trials were included, in which 143 par-
ticipants with myotonia were randomised in a single-blind or dou-
ble-blind crossover study with a treatment period ranging from
two weeks to six months. Twelve different drugs were used in those
ten trials. Participants could be divided into 113 people with my-
otonic dystrophy type 1 and 30 people with myotonia congenita.
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Three studies were performed in the 1960s, six in the 1980s and
one in the 1990s. In general the trials were small, with the partici-
pant numbers ranging from nine to thirty, and themethodological
quality was poor. All ten included randomised crossover trials were
based on a per protocol analysis which could result in an attrition
bias. The data for an intention-to-treat analysis were not available.
The data analysis of Finlay 1982 was inadequate. The study only
presented descriptive results. The individual continuous data were
not stated and no statistical analysis was performed. The data of
Kratz 1986 were incomplete because we only have the information
in the abstract (descriptive results). Attempts to contact the author
were unsuccessful. Lewis 1966 had a large placebo effect. Research
into the placebo tablets identified that they contained 0.5 mg
quinine sulphate per tablet. This substance could be an effective
treatment for myotonia, resulting in performance bias. For these
reasons we were unable to use the data from these three trials.
Six studies (Durelli 1983, testing taurine; Gascon 1989, testing
imipramine; Grant 1987, testing nifedipine; Kwiecinski 1992,
testing disopyramide, fenytoin, mexiletine and tocainde; Leyburn
1960, testing quinine, predsnion and procainamide; Munsat
1967, testing diphenylhydantoin and procainamide) were of
crossover design without washout intervals. Data were inappro-
priately presented in the form of combined results of both active
treatment arms and both placebo arms. Since a washout interval
was not incorporated, there is a strong possibility of a carry-over
effect. Data from the first arms were not presented and four studies
did not present data individually (Grant 1987; Kwiecinski 1992;
Leyburn 1960; Munsat 1967). From these four studies three in-
cluded both participants with myotonic dystrophy as well as my-
otonia congenita, without defining subgroups. For these reasons
we were unable to use data from those four trials. We tried to
contact the authors of the trials but have not yet been successful in
obtaining the raw data. Two single studies (Durelli 1982; Gascon
1989) gave data for some of our specified outcomes and in spite
of a possible carry over effect we will present these data. For one
study (Antonini 1990) we can provide the results for the treatment
of myotonia without any restrictions. Because most trials included
different diseases in the same trial without giving the individual
data and used different drug treatments, meta-analysis was not
possible.
Thus it is only possible to present the data of three studies for the
treatment of myotonia in myotonic dystrophy (Antonini 1990;
Durelli 1983; Gascon 1989). We could not present potentially
valuable data for the treatment of myotonia in myotonia con-
genita. For the Durelli 1983 study with a treatment period of six
months it is only possible to present the data for our secondary
outcomemeasure, the EMG relaxation time. The EMG relaxation
time after treatment with taurine was lower (average 0.58 seconds;
SD 0.24) than both the baseline (average 1.33 seconds; SD 0.71)
and after placebo (average 1.02 seconds; SD 0.36) (P < 0.01; Stu-
dent’s t test). Taurine had no side effects.
Gascon 1989 measured both left and right-hand relaxation times
after imipramine and placebo. Our primary outcome with the
McNemar test was significant for the right hand with an infinity
odds ratio (95% CIs from binomial distribution 0.92 to infinity)
(P = 0.025) and also significant for the left hand with an infinity
odds ratio (95% CIs from binomial distribution 0.66 to infinity)
(P value = 0.046). The relaxation timewasmeasured as a secondary
outcome. Repeated measures of analysis of variance (ANOVAs)
of these data revealed significant improvement of myotonia as
measured by right grip (F(2.20) = 11.14, P < 0.001) and left
grip (F(2.20) = 6.65, P < 0.01). The most important side effects
of imipramine were dry mouth (8 out of 12 participants; 67%),
dizziness (4 out of 12; 33%), increased sweating (4 out of 12;
33%), constipation (4 out of 12; 33%), tremor (3 out of 12; 25%),
blurred vision (3 out of 12, 23%) and diarrhoea (3 out of 12,
23%).
The trial of Antonini 1990 used clomipramine and had two
washout intervals of thirty days so the risk of carry-over effect
was reduced. They stated that there were no differences between
people receiving clomipramine in the first or second treatment
period. The primary outcome of improvement of myotonia with
the McNemar test was not significant and showed an odds ratio
of 3.00 (95% CIs 0.25 to 157.49) (P = 0.32). The analysis of a
secondary outcome with a paired t-test (crossover study) demon-
strated that the mean relaxation time after clomipramine (average
15.85 seconds, SD 9.44) was significantly shorter (P = 0.02) than
after placebo (average 22.54 seconds, SD 16.47). The study had
no electromyographic relaxation time, stair test or presence of per-
cussion myotonia as outcomes. Minor side effects were drowsiness
(6 out of 15 participants; 40%), dry mouth (2 out of 15; 13%),
tiredness (2 out of 15; 13%), hyperhydrosis (1 of 15; 7%) and
dizziness (1 of 15; 7%).
In conclusion, it was only possible to calculate our primary out-
come for two studies (Antonini 1990; Gascon 1989). This out-
come was only significant for treatment with imipramine for my-
otonia inmyotonic dystrophy (Gascon 1989). Our secondary out-
come measure of relaxation time could be calculated in the same
two studies. Both imipramine and clomipramine showed a sig-
nificant result in relieving myotonia in myotonic dystrophy. We
could only provide data for the EMG relaxation time from the
Durelli 1983 study with the treatment of taurine for myotonia in
myotonic dystrophy. This result was also significant. Meta-analy-
sis was not possible.
The side effects of the other active drug treatments taken from the
included trials were:
Mexiletine: 20% (6 of 30) epigastric distress sometimes prevented
by taking the drug with food, 3% (2/30) rash, esophageal burning
and nasal congestion.
Tocainine: 6% (1 of 18) lymphadenopathy and 11% (2 of 18)
dizziness, anxiety and tremor.
Diphantoin: 10% (3 of 30) skin rash, somnolence andmild ataxia.
Disopyramide: 32% (7 of 22) dry mouth and blurred vision while
taking high doses.
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Nifedipine: 20% (2 of 10) headache and lethargy while taking 3
doses of 20 mg and 10% (1 of 10) light T wave flattening or T
wave inversion on the ECG.
Procainamide: 39% (15 of 39) gastro-intestinal complaints.
Quinine: 45% (9 of 20) mild and tolerable tinnitus, 30% (6 of
20) some degree of deafness and 5% (1 of 20) dull head without
tinnitus.
Prednisone: no side effects in three weeks. This is of course of little
value in judging safety of steroid therapy as a long-term measure.
Diazepam: 64% (7 of 11) sedation and 27% (3 of 11) of dizziness.
The tested drug treatments in this review varied in costs fromEUR
2.29 per month (phenytoin) to EUR 23.67 per month (quinine)
(Loenen 2005).
D I S C U S S I O N
Despite the fact that different drug treatments have been used
to reduce symptoms of myotonia since 1936, very few good ran-
domised crossover trials have been performed to study the effect of
these treatments. Overall, the methodological quality of the stud-
ies considered was poor. Most methods reported in original papers
were not described in sufficient detail. Only one crossover trial had
a washout interval and reported data from each treatment period.
Clomipramine, studied in this small trial, demonstrated a signif-
icant effect on the relaxation time in participants with myotonic
dystrophy. For more reliable results it is necessary to perform stud-
ies with a larger cohort. The other crossover trials did not have
a washout interval and did not report data from each (or at least
the first) treatment period separately. Four studies included par-
ticipants with myotonic dystrophy as well as myotonia congenita
without defining subgroups. For these reasons it was not possible
to estimate the treatment effect of four studies. Two other small
studies indicated, despite a carry-over effect, a short-term effect of
imipramine and a long-term effect of taurine on myotonia in my-
otonic dystrophy. In spite of the evidence (admittedly limited) for
these three drugs reducing myotonia, they are probably not used
very often in medical practice. Expert opinion on the base of clin-
ical experience still favours mexiletine, particularly in myotonia
congenita. This is despite the lack of randomised controlled tri-
als with mexiletine although one is awaiting assessment (Martens
2005). In conclusion, better randomised crossover studies with a
proper washout interval and clearly presented data from both arms
and with clear separation of the different diseases associated with
myotonia are necessary for further determination of an effective
and safe treatment for myotonia.
The adverse events from randomised data are given in the results.
Non-randomised data suggest serious side effects for tocainide and
procainamide such as agranulocytosis and pancytopenia (Gelfand
1994; Nelson 1984; Shields 1988; Soff 1987; Wang 1969). These
serious side effects are a contraindication for their use in myoto-
nia. Other side effects of tocainide are diplopia, dizziness, nausea,
tremor and anxiety (Mielke 1985; Ricker 1980; Rüdel 1980). For
procainamide more than 50% of the participants had gastro-in-
testinal side effects and 33% complained of insomnia (Geschwind
1955). Three participants with myotonic dystrophy and treated
with phenytoin or carbamazepine had cardiac side effects (ventric-
ular tachycardia and atrioventricular block grade 1) (Durelli 1985).
Reported side effects of acetazolamidewere paraesthesias, anorexia,
weight loss, renal failure, renal calculi, osteoporosis, and haema-
tological and hepatic dysfunction (Griggs 1977; Griggs 1978). In
a non-randomised study of amitriptyline for myotonia six from
the eight participants complained of a dry mouth and two had
drowsiness. One participant had supraventricular tachycardia due
to an adrenergic effect (Milner-Brown 1990). Verapamil for my-
otonia was tested in a non-randomised study in five people. One
participant complained of dizziness with a first-degree heart block,
another had transient nausea (Cook 1984).
The lack of appropriate trials and data is not the only difficulty
in determining the treatment effect in myotonia. Difficulty also
exists in the clinical assessment of myotonia. Although many out-
come measures have been developed, until now no validated scale
has been used with unanimous consent. Sansone 2000 wrote an
experimental protocol but also reported some unsolved problems.
One of the main problems is the inter- and intra-variability of
myotonia under the same conditions and the inter rater variabil-
ity. Furthermore, myotonia can be dependent on temperature,
physical effort, rest, food intake, pregnancy, phenotype and geno-
type. Therefore, it is difficult to standardize outcome measures for
myotonia. A technique to overcome some of these problems in
measuring relaxation times, is the use of computerized protocols
in which a computer program places cursors along the relaxation
phase and calculates the relaxation times between these points
(Logigian 2004; Logigian 2005).
Another problem in determining the treatment effect of myotonia
is the intriguing warming-up phenomenon (diminishing of my-
otonia after repetitive contractions). In chloride channelopathies
this is probably the result of an improvement of both myotonia
and transient paresis (Drost 2001) and in myotonic dystrophy
and sodium channel myotonias it is only the improvement of my-
otonia. The exact pathophysiological mechanism of the warming-
up phenomenon is unknown but the phenomenon could influ-
ence the degree of myotonia, especially when measuring repeated
maximum voluntary contractions. The length and frequency of
maximum voluntary contractions differed between studies which
could influence the outcome measures. Furthermore paramyoto-
nia can occur, which is a worsening of myotonia after repetitive
contractions (paradoxical myotonia). Myotonia is thus a symptom
in different diseases. We excluded the diseases with no true myoto-
nia (see background and type of participants) but when these are
excluded there are still three groups left: (1) myotonic dystrophy
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type I (and probably type II), (2) non-dystrophic chloride channel
myotonias, and (3) non-dystrophic sodium channel myotonias.
In general myotonia is a mild symptom in myotonic dystrophy
and a much more serious symptom in myotonia congenita and
the sodium channelopathies.
Paradoxically in our review only 30 people with myotonia con-
genita were studied and themajority hadmyotonic dystrophy per-
haps reflecting the higher prevalence ofmyotonic dystrophy.How-
ever most people with myotonic dystrophy do not seek treatment
for their myotonia because it often is a relatively mild symptom
compared to the other symptoms they suffer. They also may have
an avoidant personality with “avoidance” of medical treatment as
part of their disease. All studies which included participants with
myotonia congenita included people with myotonic dystrophy
as well. This causes a mixture of different diseases with different
pathophysiologies, but the outcome measures were not analysed
for the two disorders separately. For all the reasons mentioned
above it would seem appropriate to performdifferent RCTs for the
different kinds of myotonic diseases. It is also unlikely that a single
method of assessment is appropriate for each separate disease.
Finally, there is the lack of functional outcomemeasures. Themost
used functional outcome measure is the stair test (see last part of
background), but only one study used this test. We recommend
this test as a secondary outcome measure in future RCTs. Another
possible functional test for future studies could be the chair test
(time needed to stand up from a chair, walk around the chair and
sit down again).
In conclusion, the best evidence for the treatment of myotonia in
myotonic dystrophy is from single small studies of clomipramine,
imipramine and taurine. We could not present separate data for
the treatment of myotonia in myotonia congenita. However, a
beneficial effect from drug treatment for myotonia cannot be ex-
cluded and its use in certain people with severe myotonia might
be appropriate (for example in those in whom there is a clear im-
pact on daily activities). Taurine did not have any side effects in
nine people for six months. Clomipramine and imipramine have
some side effects but seem to be safe treatments. Based on three
single small randomised trials and clinical observations (subjective
responses of the patients and expert opinion) some drugs have a
potential effect in decreasing myotonia. To prove this hypothesis,
properly designed, double-blind, randomised controlled (multi-
centre) trials have to be performed for the different types of my-
otonic disorders. In the case of crossover trials, a washout interval
is recommended.Moreover, intention-to-treat analysis and appro-
priate analysis and presentation of the results are required.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of high quality randomised evidence to determine
whether any drug treatment is safe and effective in the treatment
of myotonia.
Implications for research
The clinical efficacy of drug treatment for myotonia has not yet
been properly evaluated. Larger, well designed RCTs are needed to
assess the efficacy and tolerability of drug treatment for myotonia.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Antonini 1990
Methods Randomised, double-blind crossover study.
Method of randomisation not stated.
Single centre Italy.
Treatment periods of 33 days. Total duration 166 days.
Results presented as combined data from both active treatment arms and both placebo
arms. Two washout periods of 30 days. Results first arms stated
Participants 17 patients with 2 withdrawals.
17 patients with myotonic dystrophy.
8 patients were male, 9 female.
Mean age 29 (SD not stated)
Inclusion criteria: Well-established criteria for myotonic dystrophy.
Exclusion criteria: Subjectswith cardiac, ophthalmologic, or urologic diseaseswere excluded
Interventions Clomipramine 75 mg/day. Comparison treatment placebo.
Outcomes Gripmyotonia by relaxation time in seconds; time necessary to completely open the fist after
three seconds of maximum voluntary contraction performed by maintaining a constant
pressure in a rolled sphygmomanometer cuff
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Durelli 1983
Methods Randomised, double-blind crossover study.
Method of randomisation not stated.
Single centre Italy.
Treatment periods of 6 months. Total duration of 1 year.
Results presented as combined data from both active treatment arms and both placebo
arms. No washout period. Results first arms not stated
Participants 9 patients without withdrawals.
9 patients with myotonic dystrophy.
Number of males and females not stated.
Mean age not stated.
Inclusion criteria: Established clinical EMG-criteria.
Exclusion criteria: None stated.
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Durelli 1983 (Continued)
Interventions Taurine 100-150 mg/kg.
Comparison treatment placebo.
Outcomes EMG relaxation time after maximum voluntary contraction.
Occurence of percussion myotonia.
Occurence of myotonic discharges by electrical stimulation of median nerve.
KCl loading test in mmol/litre necessary for occurrence of myotonia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Finlay 1982
Methods Randomised, double-blind crossover study.
Method of randomisation not stated.
Single centre United Kingdom.
Treatment periods of 14 days. Total duration 28 days.
Results presented as descriptive, individually data for the four treatment arms. No washout
period. Descriptive data first arms stated
Participants 10 patients with 2 withdrawals.
10 patients with myotonic dystrophy.
7 patients were male, 3 female.
Mean age not stated. Range from 31-59 years.
Inclusion criteria: none stated.
Exclusion criteria: none stated.
Interventions Procainamide 250 mg 4x/day first week and 500 mg 4x/day second week versus disopyra-
mide 100 mg 3x/day first week and 200 mg 3x/day second week.
Comparison between both treatments.
Outcomes Grip myotonia by measuring relaxation time in seconds necessary to completely open the
fist after three minutes of maximum voluntary contraction.
Grip strength by using a RAF Gripometer.
Subjective comments.
Notes Individually continuous data not stated.
No statistical analysis.
Patients could recognize their original medicine by kind of adverse events
Risk of bias
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Finlay 1982 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Gascon 1989
Methods Randomised, double-blind crossover study.
Method of randomisation not stated.
Single centre North Dakota, USA.
Treatment periods of 6 weeks. Total duration of 12 weeks.
Results presented as combined data from both active treatment arms and both placebo
arms. No washout period. Results first arm not stated
Participants 12 patients out of a group of 23 patients with myotonic dystrophy (confirmed by well-
established criteria).
1 drop-out because of normal relaxation time.
6 patients were male, 6 female.
Mean age not stated. Range from 18-55 years.
Inclusion criteria: None stated.
Exclusion criteria: None stated.
Interventions Imipramine from 50-375 mg/day on the basis of plasma concentrations.
Comparison treatment placebo.
Outcomes Grip myotonia by measuring relaxation time after squeezing the examiner’s two fingers for
2-3 seconds.
Percussion myotonia thenar eminence after struck with reflex hammer by measuring time
in seconds.
Three successive timings of grip and percussion myotonia were taken, and the mean of
these three was used as the patient’s “score”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Grant 1987
Methods Randomised, single-blind crossover study.
Method of randomisation not stated.
Single centre Glasgow, Scotland.
Treatment periods of 2 weeks. Total duration unclear.
Results presented as combined data from both active treatment arms and both placebo
arms. No washout period. Results first arms not stated
Participants 10 patients without withdrawals.
10 patients with myotonic dystrophy.
6 patients were male, 4 female.
Mean age 40.4 (SD not stated).
Inclusion criteria: Accepted clinical criteria and electromyographic characteristics.
Exclusion criteria: None stated.
Interventions Nifedipine 10 mg 3x/day and nifedipine 20 mg 3x/day.
Comparison treatment placebo.
Outcomes Finger extension time of both hands measured as relaxation time after maximal voluntary
contraction.
The mean value of the first five extension times was measured
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Kratz 1986
Methods Randomised, double-blind crossover study.
Method of randomisation not stated.
Single centre, Washington, D.C., USA.
Treatment period not stated.
Total duration not clear.
Results presented as number of patients that improved. No insights in data.
No washout period.
Participants 6 patients without withdrawals.
4 patients with myotonic dystrophy and 2 with myotonia congenita.
Number of males, females, mean age and inclusion/exclusion criteria not stated
Interventions Mexiletine in doses up to 600 mg/day.
Outcomes Grip strength. Relaxation time after making a fist, at room temperature and after the hand
in ice water for 1 minute.
Length of myotonic discharges.
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Kratz 1986 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Kwiecinski 1992
Methods Randomised, single-blind study. At beginning a crossover trial of phenytoin and placebo.
Afterwards randomisation for disopyramide, tocainide or mexiletine.
Methods of randomisation not stated.
Single centre Poland.
Treatment periods of 4 weeks. Total duration unclear.
Results for the cross-over part of the study presented as combined data from both active
treatment arms and both placebo arms. No washout period. Results first arms not stated.
Overall results presented as outcome measures after 4 weeks of treatment
Participants 30 patients with 2 withdrawals.
9 patients with myotonic dystrophy, 9 with dominant myotonia congenita and 12 with
recessive myotonia congenita.
22 patients were male, 8 female.
Mean age 31.8 years old (SD not stated).
Inclusion criteria: Accepted clinical criteria and electromyographic characteristics for dif-
ferent diseases.
Exclusion criteria: None stated.
Interventions Fenytoin 400 mg/day for two weeks and 600 mg/day for the last two weeks.
Disopyramide 300 mg/day for two weeks and 600 mg/day for the last two weeks.
Mexiletine 400 mg/day for two weeks and 600 mg/day for the last two weeks.
Tocainide 800 mg/day for two weeks and 1200 mg/day for the last two weeks.
Comparison treatment placebo.
Outcomes Time needed to open eyes maximally after closure (Lid myotonia).
Time needed to open hand after firm closure (Hand opening).
Time needed to climb ten stairs (Stairtest).
EMG relaxation time (Afterdischarge).
Subjective responses.
Each test was repeated three times at intervals of at least ten minutes. The mean value from
three such measurements was taken as the time value for each test
Notes It is conspicuous that the sum of the number of patients in the different treatment groups
of the randomisation part of the study exceeds the total number of included patients.
Outcome measures were not measured in all patients (No reasons given)
Risk of bias
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Kwiecinski 1992 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Lewis 1966
Methods Randomised, double-blind crossover study.
Randomisation arbitrarily by secretary.
Single centre United Kingdom.
Treatment periods of 3 weeks. Total duration of 6 weeks.
Results presented as combined data from both active treatment arms and both placebo
arms. No washout period. Results first arm stated
Participants 20 patients and 13 controls.
19 patients with myotonic dystrophy and 1 with myotonia congenita.
Number of males and females not stated.
Mean age not stated.
Inclusion criteria: None stated.
Exclusion criteria; None stated.
Interventions Diazepam 5 mg 2x/day - 4x/day.
Comparison treatment placebo.
Outcomes Relaxation time with EEG surface electrodes on right forearm after 5 seconds of maximum
voluntary contraction. Value was the mean of three measurements.
Accurate progress notes with specific on grasp myotonia, percussion myotonia and toxic
effects medication
Notes Great placebo effect; research into placebo tablets pointed out that they contain 0.5 mg
quinine sulfate per tablet
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Leyburn 1960
Methods Randomised, double-blind crossover study.
Randomisation by statistician.
Single centre United Kingdom.
Treatment periods of three weeks. Total duration twelve weeks.
Results presented as individual data for different interventions and as combined data for
treatment arms and placebo arms. No washout period. Results first arm not stated
Participants 20 patients with 4 withdrawals.
16 patients with myotonic dystrophy and 4 with myotonia congenita.
9 patients were male, 11 female.
Mean age not stated.
Inclusion criteria: None stated.
Exclusion criteria: None stated.
Interventions Quinine (5 grain sugar coated tablets): 5 grains 2x/day first week and 5 grains 3x/day second
and third week.
Procainamide (0.25 g tablets): 0.5 g q.i.d first week, 0.75 g q.i.d second week and 1.0 g q.
i.d third week.
Prednisone (5 mg tablets): 10 mg b.i.d first throughout the three week period.
Comparison treatment placebo.
Outcomes Objective myotonia by measuring 3 times the after discharge with EMG and by measuring
3 times clinical relaxation time. The result is the average of all six measurements.
Subjective opinion.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Munsat 1967
Methods Randomised, double-blind crossover study.
Method of randomisation not stated.
Single centre Los Angeles, USA.
Treatment periods of three weeks. Total duration 9 weeks.
Results presented as combined data from four active treatment arms and both placebo
arms. No washout period. Results first arm not stated
Participants 9 patients without withdrawals.
7 patients with myotonic dystrophy and 2 with myotonia congenita.
Number of males and females not stated.
Mean age not stated.
Inclusion criteria: Accepted clinical criteria, electromyography and muscle biopsy. Selected
on the basis of intelligence and capability of being examined weekly and presented a spec-
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Munsat 1967 (Continued)
trum of clinical involvement.
Exclusion criteria: None stated.
Interventions Diphenylhydantoin 100 mg 2x/day first week, 3x/day second week and q.i.d third week.
Procainamide 1 g 2x/day first week, 3x/day second week and 4x/day third week.
Comparison treatment placebo.
Outcomes Ergographic evaluation of hand grasp after five seconds ofmaximumvoluntary contraction.
Subjective report regarding efficacy or toxicity or both.
Repeated ECG utilizing standard leads.
Notes Researcher could recognize medicine of patients by kind of adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alfonsi 2007 Case study.
Backman 1990 Non-randomised uncontrolled study.
Benstead 1987 Case study.
Birnberger 1975 Non-randomised uncontrolled study.
Brumback 1983 Non-randomised open study.
Cook 1984 Case study.
Durelli 1982 Non-randomised study.
Garai 1954 Case study.
Geschwind 1955 Case study.
Griggs 1977 Non-randomised study.
Griggs 1978 Non-randomised open study.
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Griggs 1989 No myotonia as outcome measure.
Guilleminault 1984 Non-randomised study.
Hughes 1991 Case studies.
Jackson 1994 Case study.
Karli 1974 Case study.
Matsumura 2004 Non-randomised open study.
Mielke 1985 Non-randomised study.
Milner-Brown 1990 Non-randomised uncontrolled study.
Müller 1980 Non-randomised open study.
Orndahl 1986 Non-randomised study.
Orndahl 1994 No myotonia as outcome measure.
Pendefunda 1974 Case study.
Pénisson-Besnier 2008 No myotonia as outcome measure.
Ricker 1980 Non-randomised open study.
Rüdel 1980 Non-randomised study.
Samaha 1964 Non-randomised study.
Schneider-Gold 2003 No myotonia as outcome measure.
Sechi 1983 Non-randomised study.
Streib 1987 Case study.
Sugino 1998 Non-randomised open study.
Tarnopolsky 2004 No myotonia as outcome measure; Only muscle forces, functional measures and activities of daily
living scales
Vlachopapadopoulou 1995 No myotonia as outcome measure.
Walter 2002 No myotonia as outcome measure.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Methodological Quality of Included Studies
Study Allocation con-
cealment
Patient blinding Observer blind-
ing
Inclusion criteria Exclusion criteria Outcome
measures
Antonini 90 B B B A A A
Durelli 83 B A A A B A
Finlay 87 B C A B B A
Gascon 89 B B A B B A
Grant 87 B B B A B A
Kwiecinski 92 B A D A B A
Lewis 66 C B A B B A
Leyburn 60 A B B B B C
Munsat 67 B A C A B A
Kratz 86 B B B B B A
Key: A:
Adequate
B: Unclear
C: Inadequate
D: Not done
WH A T ’ S N E W
Last assessed as up-to-date: 29 July 2009.
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Date Event Description
11 May 2011 Amended Acknowledgement added
H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 1, 2006
Date Event Description
12 August 2009 New search has been performed Searches updated to 30 July 2009 and minor edits un-
dertaken. No new randomised controlled trials were
identified
29 April 2008 Amended Converted to new review format.
25 February 2008 New search has been performed Searches updated to 31December 2007.One additional
study, Alfonsi 2007 added to excluded studies
5 October 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Jeroen Trip wrote the first draft. Jeroen Trip and Karin Faber independently reviewed the titles and abstracts from the electronic search
to identify trial reports. They graded the methodological quality and performed the data extraction. Karin Faber, Gea Drost and Baziel
van Engelen commented on the first and subsequent drafts. All authors agreed the final text.
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